(IN BRIEF) Novartis announced positive Phase III results from the RemIND trial showing that the oral BTK inhibitor remibrutinib achieved significantly higher complete response rates than placebo in three major forms of chronic inducible urticaria. The treatment demonstrated good tolerability … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Angelika Jahreis, autoimmune and inflammatory diseases, BTK inhibitor, chronic inducible urticaria, chronic urticaria treatment, CIndU, dermatology innovation, FDA application, global clinical trials, histamine pathway, immunology research, Novartis, Novartis Advances Immunology Pipeline with Promising Late Stage Outcomes for Oral BTK Inhibitor in Rarely Addressed Skin Disorder, Phase III study, regulatory submission, remibrutinib, RemIND trial, Rhapsido, targeted therapy development
(IN BRIEF) Novartis has reported landmark Phase III results showing that ianalumab significantly reduced disease activity in patients with Sjögren’s disease, meeting primary endpoints in both the NEPTUNUS-1 and NEPTUNUS-2 trials. The treatment, which combines B-cell depletion and BAFF-R inhibition, … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged autoimmune disease, B cell depletion, BAFF-R inhibition, biopharmaceuticals, clinical trial results, ESSDAI, Fast Track Designation, ianalumab, immunology research, MorphoSys AG, NEPTUNUS-1, NEPTUNUS-2, Novartis, Shreeram Aradhye, Sjögren’s disease, systemic autoimmune disorder, targeted therapy, US FDA, VAY736
(IN BRIEF) Amolf researcher Megan Farrell has received the Off Road grant from ZonMW to study how the immune system’s inhibitory receptors act as brakes to prevent autoimmune responses. Using cutting-edge microscopy, she will track these receptors in real time … Read the full press release
Posted in Awards, Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, Netherlands, News, Science, Technology
Tagged AMOLF, autoimmune diseases, Awards, cellular signaling, immune system, immunology research, inflammatory diseases, inhibitory receptors, Kristina Ganzinger, leadership, Megan Farrell, microscopy, Molecular Biology, nanoscale research, Off Road grant, Physics of Cellular Interaction Group, ZonMw
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?